| Institution: | 1.Department of Pathogenic Biology and Medical Immunology,Ningxia Medical University,Yinchuan,China;2.Key Laboratory of Hydatid Disease,Ningxia Medical University & Ningxia Institute of Medicine,Yinchuan,China;3.Centre of Scientific Technology of Ningxia Medical University,Yinchuan,China;4.Institute of Clinical Laboratory,Ningxia Medical University,Yinchuan,China |
| Abstract: | ObjectiveThis study aims to investigate the immunoprotection of recombinant Eg.P29 (rEg.P29) vaccine and analyze the underlying mechanism in sheep.MethodsThree groups of male sheep were immunized subcutaneously with rEg.P29 and PBS, Freund’s complete adjuvant as controls, respectively. After prime-boost vaccination, the sheep were challenged with encapsulated Echinococcus granulosus eggs. The percentage of protection in sheep was determined 36 weeks after the infection. Humoral immune response was analyzed for specific IgG, IgG1, IgG2, IgM and IgE levels. Moreover, cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4,and IL-10 were also evaluated.ResultsImmunization with rEg.P29 induced protective immune responses up to 94.5 %, compared with immunoadjuvant group. The levels of specific IgG, IgG1, IgG2, and IgE as well as IFN-γ, IL-2, and IL-4 significantly increased after two immunizations (P < 0.05); however, the levels of IgM and IL-10 did not show difference.ConclusionrEg.P29 showed Immunoprotection and induced Th1 and Th2 immune responses; hence, rEg.P29 is a potential vaccine for E. granulosus infection. |
